Mundipharma has announced today that it has sealed an exclusive sales agreement with Biosolution Co., Ltd, a Korea-based leader in cell-based biotechnology, to market and distribute its fourth-generation autologous chondrocyte implantation product, CartiLife®.
CartiLife® is an autologous cartilage-derived chondrocyte cell therapy for the treatment of cartilage defects (ICRS grade 3 or 4). Its key benefits include significantly reduced risk of host-immune rejection due to its autologous nature, direct restoration of hyaline cartilage, and a less invasive surgery followed by shorter recovery times compared to alternative, comparable therapies.
Under the agreement, Mundipharma obtains the rights to market and distribute CartiLife® in South Korea.
"We are delighted to extend our relationship with Biosolution to include CartiLife®, which adds to our portfolio of products for orthopedic care," said Mundipharma's CEO, Raman Singh. "It is also another example of our support for innovative treatments developed in Asia and our ability to increase their market presence."
This is the second deal between Mundipharma and Biosolution Co., Ltd following the exclusive sales agreement for the allogeneic keratinocyte cell therapy product, KeraHeal-Allo™, which was announced in May 2016.
About Biosolution Co., Ltd.
Biosolution Co., Ltd. manufactures and distributes pharmaceuticals. The Company produces cell therapy products, human tissue models, and other related products. Biosolution markets its products throughout South Korea. Biosolution Co., Ltd sells Keraheal, a cell therapy that has a 70 percent share in the severe burn treatment market.
Mundipharma's independent associated companies are privately owned entities covering the world's pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare.
For more information please visit: www.mundipharma.com.sg.
Mundimphara 今天宣布，已与韩国细胞生物技术领先企业 Biosolution Co ., Ltd 签订独家销售协议，销售和分销其第四代自体软骨细胞植入产品 Carti Life ®。
CartiLife ®是一种自体软骨来源软骨细胞疗法，用于治疗软骨缺损（ ICRS 等级3或4）。它的主要好处包括显著降低宿主免疫排斥的风险，因为它的自体性质，直接恢复 hyaline 软骨，以及一个较少的侵入性手术后，更短的恢复时间比替代，可比的治疗。
根据协议， Mundipharma 获得在韩国销售和分销 CartiLife ®的权利。
Mundipharma 首席执行官 Raman Singh 说：“我们很高兴与 Biosolution 扩大合作关系，将 Carti Life ®纳入我们的骨科护理产品组合。”“这也是我们支持亚洲开发的创新治疗方法的另一个例子，也是我们提高市场份额的能力。”
这是 Mundipharma 与 Biosolution Co ., Ltd 之间的第二笔交易，是在2016年5月宣布的同基因角质细胞治疗产品 KeraHeal-Allo ™的独家销售协议之后达成的。
生物解决方案有限公司生产和销售药品。本公司生产细胞治疗产品、人体组织模型等相关产品。生物解决方案将其产品销往韩国各地。生物解决方案有限公司销售 Keraheal ，一种在严重烧伤治疗市场上占70%份额的细胞疗法。
Mundipharma 的独立联营公司是覆盖全球医药市场的私有实体。Mundimpharma 是一个典型的公司，它始终提供高质量的产品，同时坚持代表公司的价值观。我们的使命是减轻癌症和非癌症疼痛患者的痛苦，并大幅提高他们的生活质量。Mundimpharma 致力于将疼痛、肿瘤、肿瘤支持治疗、眼科、呼吸系统疾病和消费者保健等领域的新的治疗方案带来给重症和弱质性疾病患者。
详情请访问： www.mundipharma.com.sg 。